Visudyne Injection 1 Vial

Frequently asked questions

• Onset of action

  The amount of time required for this medicine to show its action is not clinically established.

• Duration of Effect

  The amount of time for which this medicine remains active in the body is not clinically established.

• Safe with Alchohol?

  Use of ethanol is not recommended along with Visudyne Injection 1 Vial because it can alter the desired effects of Visudyne Injection 1 Vial .

• Is it habit forming?

  No habit-forming tendencies were reported.

• Usage in pregnancy?

  This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

• Usage while breast-feeding?

  This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

• Allergy

  This medicine is not recommended for use in patients with a known allergy to Visudyne Injection 1 Vial or any other inactive ingredients present along with it.

• Porphyria

  This medicine is not recommended for use in patients with a condition called porphyria which is a rare disorder resulting in the accumulation of porphyrin in the body.

• Pregnancy

  This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

• Breast-feeding

  This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

• Liver impairment

  This medicine should be used with caution in patients suffering from liver diseases due to the increased risk of severe adverse effects. Close monitoring of liver function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

• Light exposure

  It is advised not to get exposed to sunlight or bright indoor lights for 2 to 5 days after the therapy with this medicine due to the risk of adverse effects.

• Kidney impairment

  This medicine should be used with caution in patients with kidney diseases due to the increased risk of severe adverse effects. Close monitoring of kidney function tests, appropriate dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition.

• Use in children

  This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

• Visual disturbances

  This medicine may cause temporary visual disturbances in some patients on therapy. It is advised that you do not perform any activities that require high mental alertness like driving a vehicle or operating machinery if you experience any such symptoms.

This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.

• Usage does not depend on food timings
• To be taken as instructed by doctor
• Effect on sleep is not established

• medlineplus.gov - Verteporfin [Internet]. Available from: https://medlineplus.gov/druginfo/meds/a607060.html [cited 3/9/2020]. 2020